129 related articles for article (PubMed ID: 38423222)
21. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
[TBL] [Abstract][Full Text] [Related]
22. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract][Full Text] [Related]
23. Colorectal cancer in patients of advanced age is associated with increased incidence of
Christenson ES; Tsai HL; Le DT; Jaffee EM; Dudley J; Xian RR; Gocke CD; Eshleman JR; Lin MT
Front Oncol; 2023; 13():1193259. PubMed ID: 37350948
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors.
Xu T; Wang X; Wang Z; Deng T; Qi C; Liu D; Li Y; Ji C; Li J; Shen L
Ther Adv Med Oncol; 2022; 14():17588359221105022. PubMed ID: 35747165
[TBL] [Abstract][Full Text] [Related]
26. Tumor differentiation phenotype in gastric differentiated-type tumors and its relation to tumor invasion and genetic alterations.
Yamazaki K; Tajima Y; Makino R; Nishino N; Aoki S; Kato M; Sakamoto M; Morohara K; Kaetsu T; Kusano M
World J Gastroenterol; 2006 Jun; 12(24):3803-9. PubMed ID: 16804962
[TBL] [Abstract][Full Text] [Related]
27. BRAF
Sakamoto N; Feng Y; Stolfi C; Kurosu Y; Green M; Lin J; Green ME; Sentani K; Yasui W; McMahon M; Hardiman KM; Spence JR; Horita N; Greenson JK; Kuick R; Cho KR; Fearon ER
Elife; 2017 Jan; 6():. PubMed ID: 28072391
[TBL] [Abstract][Full Text] [Related]
28. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
[TBL] [Abstract][Full Text] [Related]
29. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
30. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer.
Mancini I; Santucci C; Sestini R; Simi L; Pratesi N; Cianchi F; Valanzano R; Pinzani P; Orlando C
J Mol Diagn; 2010 Sep; 12(5):705-11. PubMed ID: 20616366
[TBL] [Abstract][Full Text] [Related]
31. Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
Ikoma T; Shimokawa M; Kotaka M; Matsumoto T; Nagai H; Boku S; Shibata N; Yasui H; Satake H
BMC Cancer; 2021 May; 21(1):518. PubMed ID: 33962575
[TBL] [Abstract][Full Text] [Related]
32. VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.
Sajanti S; Sirniö P; Väyrynen JP; Tuomisto A; Klintrup K; Mäkelä J; Ristimäki A; Mäkinen MJ
Virchows Arch; 2014 Jun; 464(6):637-43. PubMed ID: 24722974
[TBL] [Abstract][Full Text] [Related]
33. BRAF
Zhi J; Jia XJ; Yan J; Wang HC; Feng B; Xing HY; Jia YT
World J Gastrointest Oncol; 2021 Dec; 13(12):2129-2148. PubMed ID: 35070047
[TBL] [Abstract][Full Text] [Related]
34. RNF43 germline and somatic mutation in serrated neoplasia pathway and its association with BRAF mutation.
Yan HHN; Lai JCW; Ho SL; Leung WK; Law WL; Lee JFY; Chan AKW; Tsui WY; Chan ASY; Lee BCH; Yue SSK; Man AHY; Clevers H; Yuen ST; Leung SY
Gut; 2017 Sep; 66(9):1645-1656. PubMed ID: 27329244
[TBL] [Abstract][Full Text] [Related]
35.
Gao C; Esni F; Chu E; Hu J
Biochem Biophys Rep; 2024 Mar; 37():101634. PubMed ID: 38188365
[No Abstract] [Full Text] [Related]
36. RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis.
Bond CE; McKeone DM; Kalimutho M; Bettington ML; Pearson SA; Dumenil TD; Wockner LF; Burge M; Leggett BA; Whitehall VL
Oncotarget; 2016 Oct; 7(43):70589-70600. PubMed ID: 27661107
[TBL] [Abstract][Full Text] [Related]
37. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
[TBL] [Abstract][Full Text] [Related]
38. Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp.
Cho H; Hashimoto T; Yoshida H; Taniguchi H; Ogawa R; Mori T; Hiraoka N; Saito Y; Sekine S
Histopathology; 2018 Oct; 73(4):672-680. PubMed ID: 29920740
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological features and phenotypic classification of de novo-type colorectal carcinomas differ from those of colorectal carcinomas derived from flat adenomas.
Koga Y; Hirahashi M; Ohishi Y; Oda Y
Pathol Int; 2019 Jun; 69(6):331-340. PubMed ID: 31282116
[TBL] [Abstract][Full Text] [Related]
40. Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.
Huang Y; Jia W; Zhao G; Zhao Y; Zhang S; Li Z; Wu G
Chin Clin Oncol; 2024 Feb; 13(1):3. PubMed ID: 38372057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
